PRC1 and cancer: In the nucleus, Lapatinib treatment led to the downregulation of the cell proliferation and cancer prognosis maker (KI-67), G2/mitotic-specific cyclin-B1 (CCNB1), and cell cycle G1/S and G2/M transition as a whole as represented by a highly interconnected network of nuclear proteins (AURKA, AURKB, CDK1, CDCA5, CCNB1, TOP2A, SFN, TPX2, KIF2C, KIFC1, KIF22, KIF23, NUSAP1, PRC1, ECT2, RACGAP1, FANCM, ANLN, UHRF1).